The medical devices director of the U.K. Medicines and Healthcare products Regulatory Agency has begun a monthslong timeline to retire from the position—the second top MHRA administrator to do so in the wake of Brexit after the CEO announced his own plans to step down last year.
Devices head John Wilkinson will depart at the end of October. He joined the agency in 2012 after serving as chief executive of Eucomed, the European medical technology industry association.
During his time at the MHRA, Wilkinson helped lead the agency’s efforts on the new EU regulations governing medical devices and in vitro diagnostics that took effect in May 2017.
He also chaired the Competent Authorities Medical Devices Executive, which guides regulatory collaborations between EU member states and the European Commission, and had previously been named an officer of the Order of the British Empire for his contributions to the medical device industry.
“These decisions are never easy to make, and with a very heavy heart, I have now decided to step down from my role at the Agency,” Wilkinson said in an agency statement. “I felt that now was the right time for me to move on to the next stage of my life.”
“These last seven years have been a wonderful experience for myself and I am proud to have been associated with, and worked for, the regulator,” he said. “I would like to express my deepest gratitude to my Agency colleagues with whom I’ve worked—I leave knowing that their drive and commitment in protecting public health will continue unabated.
“It’s for others to judge for themselves the work I’ve done, but my aim has always been to ensure high levels of patient safety whilst creating the right environment for medical devices to develop at a pace which continues to improve people’s lives and contributes to a sustainable development of our health services,” Wilkinson said.
Meanwhile, the CEO of the MHRA, Ian Hudson, is set to make his own exit from the agency the month before; he announced a 10-month departure plan last November.
“I had always intended to reduce my total work commitment to enable me to pursue other things and perhaps have more of a portfolio career by the time I reached 60, which has now happened,” Hudson said at the time. “I feel the time is right for a new person to guide the agency and our work through its next phase, following the U.K.’s departure from the European Union next year.”
While the full implications of Brexit remain uncertain amid delays past its March deadline, it is still possible that both Hudson and Wilkinson will leave behind a regulator forced to operate independently from the European Medicines Agency.
The new leadership will have to cope with the effects of Brexit on medical product supply, approvals, importation and other activities, including the move of the EMA’s headquarters from down the street in London’s Canary Wharf over to Amsterdam.
By Conor Hale
Source: Fierce Biotech
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.